Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia

Chimeric antigen receptor T (CAR-T) cells targeting CD19 have achieved great clinical responses in patients with relapsed or refractory (R/R) acute B lymphoblastic leukemia. However, severe adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndr...

Full description

Bibliographic Details
Main Authors: Yinqiang Zhang, Fen Zhou, Zhuolin Wu, Yingnan Li, Chenggong Li, Mengyi Du, Wenjing Luo, Haiming Kou, Cong Lu, Heng Mei
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
chimeric antigen receptor T cell
cytokine release syndrome
acute lymphoblastic leukemia
tocilizumab
interleukin-6
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.914959/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.914959/full

Similar Items